Trials / Completed
CompletedNCT00165659
A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Eisai Limited · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- —
Summary
To evaluate the dose-response efficacy of E2020 (5 mg/day and 10 mg/day) versus placebo and verify superiority of E2020 to placebo in patients with severe AD using CIBIC-plus\* and SIB\*\* as the primary efficacy measures. Safety of E2020 will also be evaluated. (\*for overall evalution of clinical symtoms) (\*\*for cognitive function test)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DONEPEZIL HYDROCHLORIDE |
Timeline
- Start date
- 2002-11-01
- Primary completion
- 2005-05-01
- First posted
- 2005-09-14
- Last updated
- 2010-01-29
Locations
65 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00165659. Inclusion in this directory is not an endorsement.